17:38 , Mar 30, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and mouse studies suggest aldose reductase inhibitors could help treat metastatic basal-like breast cancer. In metastatic breast cancer patients, levels of aldose reductase were higher in primary tumors from patients with...
07:00 , May 23, 2016 |  BC Week In Review  |  Clinical News

Diepalrestat choline: Completed Phase IIb enrollment

BioNevia and NeuroMax completed enrollment of 400 patients in the double-blind, placebo-controlled, Russian Phase IIb NM-ARI-231 trial evaluating oral BNV-222 for 1 year. BioNevia and NeuroMax are developing BNV-222. NeuroMax Ltd., Moscow, Russia   BioNevia LLC,...
07:00 , Jul 27, 2009 |  BC Week In Review  |  Clinical News

QR-333: Final phase IIb data

Final data in 140 evaluable patients in a double-blind, placebo-controlled Phase IIb trial showed that QR-333 missed the primary and secondary endpoints of significant differences in reduced pain, improved symptoms, improved quality of life and...
07:00 , May 11, 2009 |  BC Week In Review  |  Clinical News

QR-333: Phase IIb data

Quigley Corp. (NASDAQ:QGLY), Doylestown, Pa.   Product: QR-333   Business: Neurology   Molecular target: Aldose reductase   Description: Topical formulation of quercetin, ascorbyl palmitate and vitamin D3   Indication: Treat diabetic peripheral neuropathy (DPN)   Endpoint: Safety and tolerability; maximal...
08:00 , Dec 4, 2006 |  BC Week In Review  |  Clinical News

QR-333: Phase IIb started

QGLY began a 12-week, double-blind, placebo-controlled Phase IIb trial of QR-333 in up to 200 patients. Quigley Corp. (QGLY), Doylestown, Penn.   Product: QR-333   Business: Neurology   Molecular target: Aldose reductase   Description: Topical formulation of...
07:00 , Oct 2, 2006 |  BC Week In Review  |  Clinical News

QR-333: Phase IIb start

By year end, QGLY will start a 12-week, double-blind, placebo-controlled Phase IIb trial of thrice-daily QR-333 in up to 200 patients with diabetic neuropathy. Quigley Corp. (QGLY), Doylestown, Penn.   Product: QR-333   Business: Neurology   Molecular...
07:00 , Apr 17, 2006 |  BioCentury  |  Product Development

Sangamo's window panes

Ever since Genentech Inc.'s NGF failed in a Phase III trial in diabetic neuropathy in 1999, development candidates that address the disease, rather than simply palliating pain, have lacked acceptable side effect profiles. The problem...
08:00 , Mar 13, 2006 |  BC Week In Review  |  Clinical News

QR-333: IND submitted

QGLY submitted an IND to FDA to begin a Phase IIb trial to evaluate the efficacious dose range of QR-333. Quigley Corp. (QGLY), Doylestown, Penn.   Product: QR-333   Business: Neurology   Molecular target: Aldose reductase...
08:00 , Mar 13, 2006 |  BC Week In Review  |  Clinical News

QR-333: IND submitted

QGLY submitted an IND to FDA to begin a Phase II trial to evaluate safety and pharmacokinetics of QR-333. Quigley Corp. (QGLY), Doylestown, Penn.   Business: Neurology   Product: QR-333   Description: Topical formulation of quercetin, ascorbyl...
08:00 , Jan 30, 2006 |  BioCentury  |  Emerging Company Profile

Alinea: Eclectic approach to diabetes

Because of the enormous complexity of diabetes, treating the disease means not only controlling glucose, but also treating a host of neurological and cardiovascular complications. Alinea Pharmaceuticals Inc. was spun out of the Institute for...